GALENIKA IS READY FOR 2027

GALENIKA IS READY FOR 2027

Transformation that future-proofed the company

A company with 81 years of expertise, one of the leading pharmaceutical companies in Serbia and with a significant presence in international markets, has had a major launch of anti-obesity therapy this year, as well as Oli-support products supporting patients in that journey.

The man leading Galenika company for the past seven years, Ricardo Vian Marques, has shared with us his view of the industry and why Galenika brand is stronger than before.

The company you lead has been achieving steady growth year after year. Which short-term goals were reached this year and how do they fit in your long-term plans?

As a part of the Brazilian EMS Pharma Group, we have jointly worked on the anti-obesity platform in the past years.  A major breakthrough this year for us was the launch of anti-obesity therapy  in Serbia, which is GLP-1 based, as well as Oli-support line of products supporting patients in that journey. I see short-term objectives as building blocks that contribute to our long-term strategy, rather than as separate priorities. Both, our anti-obesity and Oli-support products are a part of the long-term strategy.

Besides them, we have launched 75 products in H1 2026, continued the international expansion, and entered into a more mature ESG phase, which illustrates company development, innovation, and contribution to the community. Overall, I think the biggest milestone is that we are on the firm path of stability and ongoing innovation.

Why are anti-obesity treatments such a hot topic in the pharmaceutical industry?

Global obesity statistics from the World Health Organization indicate that over 1.1 billion people – about 1 in 7 individuals worldwide – are currently living with obesity, and the numbers keep growing due to dietary shifts, sedentary lifestyles and socioeconomic factors.

Obesity is a chronic disease that requires a multidisciplinary approach with comprehensive behavioral, mental health, and environmental support. We have invested great effort in the platform that combines modern pharmacotherapy and nutritional support for sustainable results in the fight against obesity. Anti-obesity is the battle for better health and protecting organs, for longevity and an increased quality of life.

Anti-obesity therapy is crucial today because it is a widespread chronic disease that drives a great number of major health complications like heart disease, type 2 diabetes, and even cancer. Modern medications finally offer safe, highly effective weight loss. This pharmaceutical area requires long-term commitment to fight the rising global epidemic.

Galenika has gone through a real transformation journey in the past seven years. What results have you seen so far?

In short: transformation, innovation and continuity. In the wider picture, we have expanded our international business activities from 10 in year 2019, to nearly 30 markets at 4 continents. In the Serbian market we have increased our market presence and position significantly. Our portfolio was strategically expanded with relevant products. A confirmation of our strong market position is also the fact that Galenika has over 30 brands in leadership positions within their categories, according to the market share i n Serbia.

We have invested financial means, time and human resources to progress and innovate, while growing our resilience.  Also, sustainability is deeply embedded in our mission and shapes the way we grow, innovate, and contribute to the well-being of the communities we serve. It is a reflection of our organizational maturity and our ability to think long term.

Galenika 2026

How do you see the pharmaceutical industry in Serbia today compared to 7 years ago?

The pharmaceutical industry has undergone a profound change, driven by the pandemic, geopolitical and supply-chain disruptions, rapid advances in biotechnology and AI, and growing pressure to improve access and affordability. At the same time, the industry has become much more focused on resilience, digitalisation, patient-centricity, and faster development of innovative therapies. Pharma’s credibility has become an example for other industries, too. Health has become an identity, not a condition: OTC products are becoming cultural signals. The difference between products is not only built on trust, it is built on relevance.

In Serbia, we have seen similar trends, alongside stronger regulatory alignment with European standards and a steadily expanding pharmaceutical market. The competitiveness increasingly depends not only on the quality of products, but also on the ability to innovate, ensure reliable supply, adapt to regulatory change, and remain close to patients and healthcare professionals. Pharmaceutical exports have grown substantially in recent years, while new investments are strengthening Serbia’s role in regional and European pharmaceutical supply chains.

Forward looking, where do you see Galenika?

I know that Galenika is “future-ready”. It means that we have a modernized infrastructure and technology, financial stability, high-quality talent, diversified revenue from both Rx and OTC categories, and well-developed relations with partners. Our commitment to consumers is to help bring efficient, high-quality, and trusted medicines and therapies to people who need them. We are not only addressing the needs of the patients being treated, but also the needs of consumers who want to live better.

We focus on maintaining stable operations while continuously investing in our people, technology, and efficiency, while remaining agile enough to respond to market changes. Stability provides the foundation for long-term development, while innovation keeps us competitive. I believe Galenika will continue to have sustainable growth that comes from balancing discipline with innovation.


Share:
16 views